Vaccines against strains originating from avian flu may achieve poor yields in egg-based systems. Consequently, both public and private interest in alternative systems is high.
Amanda Shipman
Advertisement
Articles by Amanda Shipman
Advertisement
Latest Updated Articles
Cell-Culture–Based Manufacturing: Meeting the Challenge of 21st Century InfluenzaPublished: August 2nd 2007 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Orion and Abzena Collaboration Highlights Integrated Antibody Manufacturing Advances
2
BioPharm Weekly News Roundup—Week of Oct. 20, 2025
3
SK pharmteco Invests in California Site to Overcome Peptide Purification Bottlenecks
4
Ask the Expert: Commenting on Draft Regulations
5
